Exelixis Stock Price, News & Analysis (NASDAQ:EXEL)

$26.10 0.15 (0.58 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$26.10
Today's Range$25.95 - $26.47
52-Week Range$14.22 - $32.50
Volume3.69 million shs
Average Volume2.47 million shs
Market Capitalization$7.77 billion
P/E Ratio52.12
Dividend YieldN/A
Beta1.89

About Exelixis (NASDAQ:EXEL)

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone+1-650-8377000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.32%
Quick Ratio4.27%

Price-To-Earnings

Trailing P/E Ratio52.12
Forward P/E Ratio53.27
P/E Growth1.19

Sales & Book Value

Annual Sales$191.45 million
Price / Sales40.33
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book84.19

Profitability

Trailing EPS$0.49
Net Income$-70,220,000.00
Net Margins36.80%
Return on Equity105.47%
Return on Assets27.22%

Miscellaneous

Employees287
Outstanding Shares295,850,000

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.26 EPS for the quarter, topping the Zacks' consensus estimate of $0.08 by $0.18. The biotechnology company had revenue of $152.50 million for the quarter, compared to analyst estimates of $104.91 million. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The firm's revenue for the quarter was up 145.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. View Exelixis' Earnings History.

When will Exelixis make its next earnings announcement?

Exelixis is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Exelixis.

Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?

12 brokers have issued 1 year price objectives for Exelixis' shares. Their forecasts range from $26.00 to $39.00. On average, they expect Exelixis' share price to reach $31.29 in the next twelve months. View Analyst Ratings for Exelixis.

What are Wall Street analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:

  • 1. According to Zacks Investment Research, "Exelixis received a significant boost with the approval of the tablet formulation of cabozantinib, (distinct from the capsule form) under the brand name Cabometyx for the treatment of RCC in patients. New patient starts, refills for patients already on therapy and continued expansion of the prescriber base for Cabometyx are driving the drug’s sales. Meanwhile, Exelixis is developing cabozantinib in a broad development program and hassubmitted a supplemental New Drug Application (sNDA) for advanced RCC. The FDA assigned a PDUFA action date of Feb 15, 2018. A potential label expansion of Cabometyx will significantly boost the growth prospects. Exelixis also has collaborations with Bristol-Myers and Roche on the development of the drug in combination with immunotherapy agents. Moreover, Exelixis’ share price has outperformed the industry year to date. However, the company is heavily dependent on Cabometyx for growth." (10/18/2017)
  • 2. Cann analysts commented, "Exelixis, Inc. announced today that FDA has granted Priority Review of its supplemental New Drug Application (sNDA) for Cabometyx (cabozantinib) for patients with previously untreated advanced renal cell carcinoma (RCC). FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 15, 2018. We have modeled that Cabometyx will expand into the front-line RCC setting by 2019, but based on the timing of the PDUFA date for this indication, we now believe it could happen sooner." (10/16/2017)

Are investors shorting Exelixis?

Exelixis saw a decrease in short interest in November. As of November 15th, there was short interest totalling 17,632,404 shares, a decrease of 11.3% from the October 31st total of 19,883,248 shares. Based on an average daily volume of 3,193,602 shares, the days-to-cover ratio is presently 5.5 days. Currently, 6.2% of the company's stock are short sold.

Who are some of Exelixis' key competitors?

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder (Age 68)
  • Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director (Age 56)
  • Christopher J. Senner, Chief Financial Officer, Executive Vice President (Age 49)
  • Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer (Age 60)
  • Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer (Age 56)
  • Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary (Age 48)
  • Patrick Haley, Senior Vice President - Commercial (Age 41)
  • Charles M. Cohen Ph.D., Independent Director (Age 66)
  • Carl B. Feldbaum Esq., Independent Director (Age 73)
  • Alan M. Garber M.D. Ph.D., Independent Director (Age 61)

Who owns Exelixis stock?

Exelixis' stock is owned by many different of institutional and retail investors. Top institutional investors include Meditor Group Ltd (5.93%), Old Mutual Global Investors UK Ltd. (1.42%), Jennison Associates LLC (1.03%), Wells Fargo & Company MN (1.03%), Pictet Asset Management Ltd. (0.45%) and Macquarie Group Ltd. (0.43%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Who sold Exelixis stock? Who is selling Exelixis stock?

Exelixis' stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Old Mutual Global Investors UK Ltd., Los Angeles Capital Management & Equity Research Inc., KBC Group NV, Prudential Financial Inc., Ameriprise Financial Inc., Public Employees Retirement System of Ohio and Sei Investments Co.. Company insiders that have sold Exelixis company stock in the last year include Carl B Feldbaum, Charles Cohen, Christopher J Senner, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Who bought Exelixis stock? Who is buying Exelixis stock?

Exelixis' stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., First Trust Advisors LP, Wells Fargo & Company MN, First Quadrant L P CA, Canada Pension Plan Investment Board, Pictet Asset Management Ltd., SG Americas Securities LLC and Jennison Associates LLC. View Insider Buying and Selling for Exelixis.

How do I buy Exelixis stock?

Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of Exelixis stock can currently be purchased for approximately $26.10.

How big of a company is Exelixis?

Exelixis has a market capitalization of $7.77 billion and generates $191.45 million in revenue each year. The biotechnology company earns $-70,220,000.00 in net income (profit) each year or $0.49 on an earnings per share basis. Exelixis employs 287 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 210 E Grand Ave, SOUTH SAN FRANCISCO, CA 94080-4811, United States. The biotechnology company can be reached via phone at +1-650-8377000 or via email at [email protected]


MarketBeat Community Rating for Exelixis (EXEL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  493
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Exelixis (NASDAQ:EXEL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.582.60
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.32$29.32$26.20$17.60
Price Target Upside: 1.04% upside1.04% upside3.80% downside8.55% downside

Exelixis (NASDAQ:EXEL) Consensus Price Target History

Price Target History for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ:EXEL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Needham & Company LLCBoost Price TargetBuy$30.00 -> $33.00N/AView Rating Details
10/17/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$33.00 -> $39.00N/AView Rating Details
10/17/2017Stifel NicolausReiterated RatingHold$26.00N/AView Rating Details
10/16/2017Piper Jaffray CompaniesReiterated RatingOverweightN/AView Rating Details
10/16/2017OppenheimerReiterated RatingHoldN/AView Rating Details
10/16/2017SunTrust BanksBoost Price TargetBuy -> Buy$32.00 -> $35.00N/AView Rating Details
10/16/2017CannReiterated RatingHoldN/AView Rating Details
9/22/2017Leerink SwannDowngradeOutperform -> Market Perform$34.00 -> $28.00HighView Rating Details
8/10/2017CowenReiterated RatingOutperformMediumView Rating Details
8/3/2017Deutsche BankDowngradeBuy -> Hold$26.00 -> $29.00MediumView Rating Details
7/27/2017William BlairReiterated RatingOutperformMediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
9/28/2016S&P Equity ResearchBoost Price Target$13.41 -> $15.57N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Exelixis (NASDAQ:EXEL) Earnings History and Estimates Chart

Earnings by Quarter for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ EXEL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018$0.12N/AView Earnings Details
11/1/2017Q3 2017$0.08$0.26$104.91 million$152.50 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.04$0.06$85.27 million$99.01 millionViewListenView Earnings Details
5/1/2017Q1 2017($0.01)$0.05$65.23 million$80.90 millionViewListenView Earnings Details
2/27/2017Q416($0.01)$0.12$64.88 million$77.58 millionViewListenView Earnings Details
11/3/2016Q316($0.13)($0.04)$43.15 million$62.19 millionViewN/AView Earnings Details
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Exelixis (NASDAQ:EXEL) Earnings Estimates

2017 EPS Consensus Estimate: $0.17
2018 EPS Consensus Estimate: $0.66
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.03)$0.01($0.01)
Q2 20174$0.01$0.03$0.02
Q3 20174$0.05$0.07$0.07
Q4 20174$0.07$0.12$0.10
Q1 20182$0.09$0.13$0.11
Q2 20182$0.11$0.15$0.13
Q3 20182$0.16$0.17$0.17
Q4 20182$0.22$0.29$0.26
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Exelixis (NASDAQ EXEL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 81.19%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Exelixis (NASDAQ EXEL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2017Gisela SchwabInsiderSell100,000$23.79$2,379,000.00View SEC Filing  
9/28/2017Jeffrey HessekielEVPSell27,302$24.28$662,892.56View SEC Filing  
9/22/2017Stelios PapadopoulosDirectorSell10,000$25.40$254,000.00View SEC Filing  
9/19/2017Stelios PapadopoulosDirectorSell200,000$27.68$5,536,000.00View SEC Filing  
9/18/2017Stelios PapadopoulosDirectorSell72,210$27.76$2,004,549.60View SEC Filing  
9/14/2017Michael MorrisseyInsiderSell300,000$26.90$8,070,000.00View SEC Filing  
9/14/2017Patrick J. HaleyVPSell60,640$27.21$1,650,014.40View SEC Filing  
9/13/2017Lance WillseyDirectorSell100,000$26.88$2,688,000.00View SEC Filing  
9/12/2017Christopher J. SennerCFOSell100,000$26.79$2,679,000.00View SEC Filing  
5/30/2017Patrick J. HaleyInsiderSell5,000$18.46$92,300.00View SEC Filing  
5/15/2017Carl B FeldbaumDirectorSell32,988$21.58$711,881.04View SEC Filing  
5/10/2017Michael MorrisseyInsiderSell211,300$21.87$4,621,131.00View SEC Filing  
5/9/2017Michael MorrisseyCEOSell100,000$21.69$2,169,000.00View SEC Filing  
5/8/2017Michael MorrisseyCEOSell11,300$21.81$246,453.00View SEC Filing  
5/5/2017Michael MorrisseyInsiderSell259,149$22.24$5,763,473.76View SEC Filing  
5/1/2017Gisela SchwabCMOSell89,910$23.01$2,068,829.10View SEC Filing  
4/3/2017Vincent T MarchesiDirectorSell10,000$21.30$213,000.00View SEC Filing  
3/31/2017Jack L WyszomierskiDirectorSell5,150$21.57$111,085.50View SEC Filing  
3/27/2017Jeffrey HessekielEVPSell6,884$21.02$144,701.68View SEC Filing  
3/22/2017Jeffrey HessekielEVPSell23,787$20.54$488,584.98View SEC Filing  
3/20/2017Stelios PapadopoulosDirectorSell10,000$21.66$216,600.00View SEC Filing  
3/13/2017Charles CohenDirectorSell10,000$21.82$218,200.00View SEC Filing  
3/10/2017Vincent T MarchesiDirectorSell40,000$21.98$879,200.00View SEC Filing  
3/6/2017Michael MorrisseyInsiderSell200,000$22.72$4,544,000.00View SEC Filing  
3/3/2017Christopher J. SennerCFOSell11,000$22.80$250,800.00View SEC Filing  
3/2/2017George PosteDirectorSell76,250$22.53$1,717,912.50View SEC Filing  
1/3/2017Peter LambEVPSell70,000$14.65$1,025,500.00View SEC Filing  
12/16/2016Carl B. FeldbaumDirectorSell25,000$17.03$425,750.00View SEC Filing  
12/9/2016Alan M. GarberDirectorSell7,832$16.90$132,360.80View SEC Filing  
12/7/2016George A. ScangosDirectorSell204,894$17.81$3,649,162.14View SEC Filing  
12/5/2016George A. ScangosDirectorSell204,718$17.81$3,646,027.58View SEC Filing  
12/1/2016Gisela SchwabInsiderSell22,000$16.73$368,060.00View SEC Filing  
12/1/2016Peter LambEVPSell70,000$16.66$1,166,200.00View SEC Filing  
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Exelixis (NASDAQ EXEL) News Headlines

Source:
DateHeadline
Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : December 15, 2017Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : December 15, 2017
finance.yahoo.com - December 15 at 9:59 AM
Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long RunWhy Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run
investorplace.com - December 12 at 11:20 AM
Exelixis, Inc. (EXEL) Expected to Post Quarterly Sales of $117.71 MillionExelixis, Inc. (EXEL) Expected to Post Quarterly Sales of $117.71 Million
www.americanbankingnews.com - December 11 at 2:32 PM
Financial Comparison: Exelixis (EXEL) and The CompetitionFinancial Comparison: Exelixis (EXEL) and The Competition
www.americanbankingnews.com - December 9 at 11:42 PM
Zacks: Analysts Expect Exelixis, Inc. (EXEL) to Post $0.12 EPSZacks: Analysts Expect Exelixis, Inc. (EXEL) to Post $0.12 EPS
www.americanbankingnews.com - December 9 at 5:30 AM
Is Exelixis, Inc. a Buy?Is Exelixis, Inc. a Buy?
finance.yahoo.com - December 7 at 9:53 AM
Contrasting Exelixis (EXEL) & Its CompetitorsContrasting Exelixis (EXEL) & Its Competitors
www.americanbankingnews.com - December 6 at 9:30 AM
Exelixis, Inc. (EXEL) Given Consensus Rating of "Buy" by BrokeragesExelixis, Inc. (EXEL) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 4 at 8:24 AM
Stocks To Watch: Exelixis Sees Relative Strength Rating Rise To 84Stocks To Watch: Exelixis Sees Relative Strength Rating Rise To 84
finance.yahoo.com - December 2 at 9:43 AM
Short Interest in Exelixis, Inc. (EXEL) Drops By 11.3%Short Interest in Exelixis, Inc. (EXEL) Drops By 11.3%
www.americanbankingnews.com - November 28 at 2:38 AM
Gauging Exelixis’s High Hopes for CotellicGauging Exelixis’s High Hopes for Cotellic
finance.yahoo.com - November 24 at 10:38 AM
Your Daily Pharma Scoop: Exelixis Still Attractive, Portolas BevyxXa, Pluristem Patent - Seeking AlphaYour Daily Pharma Scoop: Exelixis Still Attractive, Portola's BevyxXa, Pluristem Patent - Seeking Alpha
seekingalpha.com - November 23 at 4:26 PM
Zacks: Brokerages Anticipate Exelixis, Inc. (EXEL) Will Post Quarterly Sales of $117.71 MillionZacks: Brokerages Anticipate Exelixis, Inc. (EXEL) Will Post Quarterly Sales of $117.71 Million
www.americanbankingnews.com - November 23 at 4:02 PM
Cabozantinib Franchise Will Continue To Transform Exelixis Fortunes In 2018 - Seeking AlphaCabozantinib Franchise Will Continue To Transform Exelixis' Fortunes In 2018 - Seeking Alpha
seekingalpha.com - November 23 at 12:12 AM
Exelixis (EXEL) to Present Phase 3 CELESTIAL Trial Results of Cabozantinib at 2018 ASCO-GI SymposiumExelixis (EXEL) to Present Phase 3 CELESTIAL Trial Results of Cabozantinib at 2018 ASCO-GI Symposium
www.streetinsider.com - November 22 at 7:11 PM
Behind Exelixis’s Cabometyx Strategy for 2018Behind Exelixis’s Cabometyx Strategy for 2018
finance.yahoo.com - November 22 at 7:11 PM
Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : November 21, 2017Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : November 21, 2017
finance.yahoo.com - November 22 at 4:42 AM
Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations - Business Wire (press release)Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations - Business Wire (press release)
www.businesswire.com - November 21 at 6:40 PM
Exelixis and Peers in November: Analyst RecommendationsExelixis and Peers in November: Analyst Recommendations
finance.yahoo.com - November 21 at 6:40 PM
What’s Really Driving Exelixis’s 2017 Revenues?What’s Really Driving Exelixis’s 2017 Revenues?
finance.yahoo.com - November 21 at 6:40 PM
Reading the Expectations for Exelixis’s Net Profit Margin in 2017Reading the Expectations for Exelixis’s Net Profit Margin in 2017
finance.yahoo.com - November 21 at 6:40 PM
Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers SymposiumExelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium
finance.yahoo.com - November 21 at 6:40 PM
Exelixis Announces Webcasts of Upcoming November Investor Conference PresentationsExelixis Announces Webcasts of Upcoming November Investor Conference Presentations
finance.yahoo.com - November 21 at 6:40 PM
$0.12 Earnings Per Share Expected for Exelixis, Inc. (EXEL) This Quarter$0.12 Earnings Per Share Expected for Exelixis, Inc. (EXEL) This Quarter
www.americanbankingnews.com - November 21 at 5:32 AM
ETFs with exposure to Exelixis, Inc. : November 20, 2017ETFs with exposure to Exelixis, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 7:14 PM
Exelixis: Primed For Excellence - Seeking AlphaExelixis: Primed For Excellence - Seeking Alpha
seekingalpha.com - November 17 at 5:18 PM
Legal Departments of the Year, Product Counseling, Emerging Companies: ExelixisLegal Departments of the Year, Product Counseling, Emerging Companies: Exelixis
finance.yahoo.com - November 14 at 12:00 AM
Better Buy: Exelixis, Inc. vs. Novartis AG - NasdaqBetter Buy: Exelixis, Inc. vs. Novartis AG - Nasdaq
www.nasdaq.com - November 13 at 7:00 PM
ETFs with exposure to Exelixis, Inc. : November 9, 2017ETFs with exposure to Exelixis, Inc. : November 9, 2017
finance.yahoo.com - November 10 at 2:33 PM
Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : November 10, 2017Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : November 10, 2017
finance.yahoo.com - November 10 at 2:33 PM
Exelixis, Inc. (EXEL) Given Average Rating of "Buy" by BrokeragesExelixis, Inc. (EXEL) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 9 at 8:12 AM
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View CutJazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut
finance.yahoo.com - November 9 at 2:38 AM
Exelixis to Present at the Stifel 2017 Healthcare Conference on November 14 - Business Wire (press release)Exelixis to Present at the Stifel 2017 Healthcare Conference on November 14 - Business Wire (press release)
www.businesswire.com - November 8 at 6:45 AM
Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasnt Too Shabby - Motley FoolExelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby - Motley Fool
www.fool.com - November 8 at 6:45 AM
Exelixis to Present at the Stifel 2017 Healthcare Conference on November 14thExelixis to Present at the Stifel 2017 Healthcare Conference on November 14th
finance.yahoo.com - November 8 at 6:45 AM
Exelixis, Inc. 2017 Q3 - Results - Earnings Call SlidesExelixis, Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 6 at 8:15 PM
Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too ShabbyExelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby
finance.yahoo.com - November 6 at 8:14 PM
Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasnt Too ShabbyExelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby
www.fool.com - November 6 at 3:38 PM
Brokers Set Expectations for Exelixis, Inc.s FY2017 Earnings (EXEL)Brokers Set Expectations for Exelixis, Inc.'s FY2017 Earnings (EXEL)
www.americanbankingnews.com - November 6 at 5:50 AM
FY2017 EPS Estimates for Exelixis, Inc. Lifted by Analyst (EXEL)FY2017 EPS Estimates for Exelixis, Inc. Lifted by Analyst (EXEL)
www.americanbankingnews.com - November 6 at 5:50 AM
Exelixis, Inc. to Post FY2017 Earnings of $0.44 Per Share, Leerink Swann Forecasts (EXEL)Exelixis, Inc. to Post FY2017 Earnings of $0.44 Per Share, Leerink Swann Forecasts (EXEL)
www.americanbankingnews.com - November 6 at 5:50 AM
Exelixis, Inc. to Post FY2017 Earnings of $0.49 Per Share, William Blair Forecasts (EXEL)Exelixis, Inc. to Post FY2017 Earnings of $0.49 Per Share, William Blair Forecasts (EXEL)
www.americanbankingnews.com - November 6 at 5:50 AM
Exelixis: Strong Earnings Coupled With Promising Prospects ... - Seeking AlphaExelixis: Strong Earnings Coupled With Promising Prospects ... - Seeking Alpha
seekingalpha.com - November 3 at 6:57 PM
The Clear Reason Exelixis, Inc. Rocketed Higher by as Much as 10% - Motley FoolThe Clear Reason Exelixis, Inc. Rocketed Higher by as Much as 10% - Motley Fool
www.fool.com - November 3 at 6:57 PM
Exelixis Scores Relative Strength Rating UpgradeExelixis Scores Relative Strength Rating Upgrade
finance.yahoo.com - November 3 at 12:34 PM
Radius Health (RDUS) Earnings Miss in Q3, Tymlos in FocusRadius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus
finance.yahoo.com - November 3 at 12:34 PM
3 Reasons Behind Exelixis Stock's Big Bounce3 Reasons Behind Exelixis Stock's Big Bounce
finance.yahoo.com - November 3 at 12:34 PM
Exelixis, Inc. :EXEL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Exelixis, Inc. :EXEL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 12:34 PM
Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 ViewSucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View
finance.yahoo.com - November 2 at 7:46 PM
Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx SalesExelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales
finance.yahoo.com - November 2 at 7:46 PM

SEC Filings

Exelixis (NASDAQ:EXEL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Exelixis (NASDAQ:EXEL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Exelixis (NASDAQ EXEL) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.